|
1）Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007; 356: 1140-51
|
|
|
|
2）Minamino T, Komuro I. Vascular cell senescence: contribution to atherosclerosis. Circ Res. 2007; 100: 15-26
|
|
|
|
|
|
3）Minamino T, Kourembanas S. Mechanisms of telomerase induction during vascular smooth muscle cell proliferation. Circ Res. 2001; 89: 237-43
|
|
|
|
|
|
4）Minamino T, Miyauchi H, Yoshida T, et al. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation. 2002; 105: 1541-4
|
|
|
|
|
|
5）Sano M, Minamino T, Toko H, et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 2007; 446: 444-8
|
|
|
|
|
|
6）Taguchi A, Wartschow LM, White MF. Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science. 2007; 317: 369-72
|
|
|
|
|
|
7）Clancy DJ, Gems D, Harshman LG, et al. Extension of life-span by loss of CHICO, a Drosophila insulin receptor substrate protein. Science. 2001; 292: 104-6
|
|
|
|
|
|
8）Bluher M, Kahn BB, Kahn CR. Extended longevity in mice lacking the insulin receptor in adipose tissue. Science. 2003; 299: 572-4
|
|
|
|
|
|
9）Tatar M, Kopelman A, Epstein D, et al. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science. 2001; 292: 107-10
|
|
|
|
|
|
10）Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009; 325: 201-4
|
|
|
|
|
|
11）Minamino T, Komuro I. Vascular aging: insights from studies on cellular senescence, stem cell aging, and progeroid syndromes. Nat Clin Pract Cardiovasc Med. 2008; 5: 637-48
|
|
|
|
|
|
12）Cawthon RM, Smith KR, OʼBrien E, et al. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003; 361: 393-5
|
|
|
|
|
|
13）Liu B, Wang J, Chan KM, et al. Genomic instability in laminopathy-based premature aging. Nat Med. 2005; 11: 780-5
|
|
|
|
|
|
14）Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444: 860-7
|
|
|
|
|
|
15）Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009; 15: 914-20
|
|
|
|
|
|
16）Charo IF. Macrophage polarization and insulin resistance: PPARgamma in control. Cell Metab. 2007; 6: 96-8
|
|
|
|
|
|
17）Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-808
|
|
|
|
|
|
18）Wessells RJ, Fitzgerald E, Cypser JR, et al. Insulin regulation of heart function in aging fruit flies. Nat Genet. 2004; 36: 1275-81
|
|
|
|
|
|
19）Shimizu I, Minamino T, Toko H, et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin Invest. 2010; 120: 1506-14
|
|
|
|
|
|
20）Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007; 116: 434-48
|
|
|
|
|
|
21）Lopaschuk GD, Folmes CD, Stanley WC. Cardiac energy metabolism in obesity. Circ Res. 2007; 101: 335-47
|
|
|
|
|
|
22）Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol. 2008; 51: 93-102
|
|
|
|
|
|
23）Arnlov J, Lind L, Zethelius B, et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J. 2001; 142: 720-4
|
|
|
|
|
|
24）Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-59
|
|
|
|
|
|
25）Shimizu I, Yoshida Y, Katsuno T, et al. p53-induced adipose tissue inflammation is critically involved in the development of insulin resistance in heart failure. Cell Metab. 2012; 15: 51-64
|
|
|
|
|
|
26）Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007; 93: 968-73
|
|
|
|
|
|
27）Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009; 53: 1925-32
|
|
|
|
|
|
28）Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001; 38: 789-95
|
|
|
|
|
|
29）Fonarow GC, Srikanthan P, Costanzo MR, et al. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J. 2007; 153: 74-81
|
|
|
|
|